Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2020-04-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
2020年度预计发生的日常经营性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's expected related party transactions for the year 2020. It includes descriptions of the nature of these transactions, the parties involved, approval procedures by the board, and financial figures related to these transactions. The document is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is also not a notice of dividend, capital change, or merger activity. The content focuses on disclosure of related party transactions, which is a regulatory requirement for listed companies to inform shareholders and the market about transactions with related parties to ensure transparency and compliance. Such disclosures typically fall under regulatory filings or announcements related to corporate governance and compliance. Given the detailed nature and the regulatory context, but not fitting other specific categories, the best classification is Regulatory Filings (RNS). The document length (9017 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive regulatory disclosure.
2020-04-24 Chinese
会计师事务所出具的对公司募集资金存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Deposit and Use of Raised Funds." It includes detailed financial data about the raised funds, their management, usage, and compliance with regulatory requirements, specifically referencing the Shanghai Stock Exchange's rules on raised funds management. The document contains an auditor's verification opinion, detailed tables of fund usage, and compliance statements. This is a specialized audit report focusing on the use of capital raised by the company, not a full annual report or earnings release. It is not a mere announcement or certification but contains substantive financial and compliance information. Therefore, it fits best under the category of Audit Report / Information (AR).
2020-04-24 Chinese
关于募集资金年度存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the annual storage and usage of raised funds by TianShiLi Pharmaceutical Group Co., Ltd. It includes specifics on the amount of funds raised, their management, usage, and any changes in investment projects related to the raised funds. The document references regulatory approvals, detailed financial figures, and compliance with relevant laws and stock exchange rules. It also contains attachments with tables showing the usage and changes in the raised funds. The content is focused on the management and use of capital raised through a non-public stock issuance, which aligns with a Capital/Financing Update. The document is substantive and not merely an announcement or certification, and it does not fit the definitions of annual reports, audit reports, or other categories. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-04-24 Chinese
第七届董事会第14次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 14th meeting of the 7th Board of Directors of TianShiLi Pharmaceutical Group Co., Ltd. It includes voting results on various reports and proposals related to the 2019 fiscal year, such as the 2019 annual general manager work report, board work report, independent director reports, audit committee reports, financial statements, profit distribution plan, annual report, social responsibility report, internal control reports, and other corporate governance matters. The document also references that the full reports are available on the Shanghai Stock Exchange website, indicating this document itself is not the full annual report but an announcement of board meeting decisions and approvals. The presence of voting results and the nature of the content align with a Declaration of Voting Results & Voting Rights Announcements filing. The document length is about 4537 characters, which is consistent with an announcement rather than a full report. Therefore, the most appropriate classification is DVA (Declaration of Voting Results & Voting Rights Announcements).
2020-04-24 Chinese
2020年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled '2020年第一季度报告' which translates to '2020 First Quarter Report'. It contains detailed financial data including balance sheet items, profit and loss items, cash flow statements, and explanations of significant changes compared to prior periods. The report covers a period shorter than a full fiscal year (the first quarter of 2020). It includes actual financial statements and substantive financial data and analysis, not just an announcement or summary. The document length is 5805 characters, which is sufficient to contain a full interim report. There is no indication that this is merely an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-24 Chinese
会计师事务所出具的对公司募集资金存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Deposit and Use of Raised Funds." It includes detailed financial data about the raised funds, their management, usage, and compliance with regulatory requirements. The report is prepared by the company's board and verified by an independent accounting firm, referencing specific regulatory guidelines from the Shanghai Stock Exchange and the China Securities Regulatory Commission. The document contains substantive financial data and analysis related to the use of capital raised by the company, including tables of fund usage and management. This type of document is a specialized audit or verification report focusing on the use of capital raised by the company, which fits the category of Audit Report / Information (AR). It is not a full annual report (10-K), nor a simple announcement or certification. Therefore, the appropriate classification is AR with high confidence.
2020-04-24 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.